{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:59:20Z","timestamp":1786996760067,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.semarthrit.2017.10.002","type":"journal-article","created":{"date-parts":[[2017,10,11]],"date-time":"2017-10-11T08:32:17Z","timestamp":1507710737000},"page":"741-748","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris, France"],"prefix":"10.1016","volume":"47","author":[{"given":"J\u00e9r\u00f4me","family":"Avouac","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Molt\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vered","family":"Abitbol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Etcheto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axelle","family":"Salcion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loriane","family":"Gutermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Klotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Elhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre Antoine","family":"Soret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Morin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ornella","family":"Conort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Chast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Goulvestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire Le","family":"Jeunne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislas","family":"Chaussade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Kahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Allanore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Dougados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2017.10.002_bib1","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1136\/ard.2009.109983","article-title":"Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database","volume":"68","author":"Sokka","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.semarthrit.2017.10.002_bib2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.biologicals.2016.03.006","article-title":"Switching to biosimilar infliximab (CT-P13): evidence of clinical safety, effectiveness and impact on public health","volume":"44","author":"Braun","year":"2016","journal-title":"Biologicals"},{"key":"10.1016\/j.semarthrit.2017.10.002_bib3","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"issue":"Suppl. 1","key":"10.1016\/j.semarthrit.2017.10.002_bib4","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1007\/s10198-014-0595-3","article-title":"Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries","volume":"15","author":"Brodszky","year":"2014","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.semarthrit.2017.10.002_bib5","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","article-title":"A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study","volume":"72","author":"Park","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.10.002_bib6","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","article-title":"A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study","volume":"72","author":"Yoo","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.10.002_bib7","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.semarthrit.2017.10.002_bib8","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","article-title":"Validation of a combined comorbidity index","volume":"47","author":"Charlson","year":"1994","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.semarthrit.2017.10.002_bib9","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/acr.20671","article-title":"Nonsteroidal antiinflammatory drug intake according to the Assessment of SpondyloArthritis International Society Score in clinical trials evaluating tumor necrosis factor blockers: example of etanercept in advanced ankylosing spondylitis","volume":"64","author":"Dougados","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2017.10.002_bib10","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1136\/ard.49.11.916","article-title":"Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score","volume":"49","author":"van der Heijde","year":"1990","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.10.002_bib11","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.10.002_bib12","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/ard.2008.094870","article-title":"Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis","volume":"68","author":"Lukas","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.10.002_bib13","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A simple index of Crohn's-disease activity","volume":"1","author":"Harvey","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2017.10.002_bib14","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2017.10.002_bib15","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00296-016-3593-1","article-title":"Development of an activity disease score in patients with uveitis (UVEDAI)","volume":"37","author":"Pato","year":"2017","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2017.10.002_bib16","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1136\/annrheumdis-2016-210742","article-title":"A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry","volume":"76","author":"Glintborg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.10.002_bib17","first-page":"297","article-title":"Switching from Remicade(R) to Remsima(R) is well tolerated and feasible: a prospective, open-label study","volume":"11","author":"Buer","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.semarthrit.2017.10.002_bib18","first-page":"593","article-title":"Comparable immune function inhibition by the infliximab biosimilar CT-P13: implications for treatment of inflammatory bowel disease","volume":"11","author":"Lim","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.semarthrit.2017.10.002_bib19","article-title":"Subjective complaints as main reason for biosimilar discontinuation after open label transitioning from originator to biosimilar infliximab","author":"Tweehuysen","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.10.002_bib20","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","article-title":"Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial","volume":"389","author":"Jorgensen","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2017.10.002_bib21","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2147\/PPA.S129333","article-title":"Assessing physician and patient acceptance of infliximab biosimilars in rheumatoid arthritis, ankylosing spondyloarthritis and psoriatic arthritis across Germany","volume":"11","author":"Waller","year":"2017","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.semarthrit.2017.10.002_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2015.07.020","article-title":"All-cause mortality associated with TNF-\u03b1 inhibitors in rheumatoid arthritis: a meta-analysis of randomized controlled trials","volume":"128","author":"Poiroux","year":"2015","journal-title":"Am J Med."},{"key":"10.1016\/j.semarthrit.2017.10.002_bib23","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1136\/annrheumdis-2016-209270","article-title":"Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers","volume":"76","author":"Hellgren","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.10.002_bib24","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1517\/14740338.2016.1160054","article-title":"The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis","volume":"15","author":"Hernandez","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.semarthrit.2017.10.002_bib25","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1136\/annrheumdis-2013-204851","article-title":"Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"74","author":"Mercer","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.10.002_bib26","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1136\/annrheumdis-2013-204575","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"73","author":"Ramiro","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.10.002_bib27","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.gtc.2014.05.002","article-title":"Miscellaneous adverse events with biologic agents (excludes infection and malignancy)","volume":"43","author":"Feuerstein","year":"2014","journal-title":"Gastroenterol Clin North Am"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017217304365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017217304365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T09:24:03Z","timestamp":1570181043000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017217304365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0049017217304365"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2017.10.002","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris, France","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2017.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}